JPMorgan Chase & Co. Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price

Lexeo Therapeutics (NASDAQ:LXEO) had its price target lowered by equities researchers at JPMorgan Chase & Co. from $12.00 to $9.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 87.42% from the company’s current price.

A number of other analysts have also commented on LXEO. Wall Street Zen raised shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Chardan Capital reaffirmed a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a research report on Monday, May 11th. Finally, Weiss Ratings upgraded shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.75.

Lexeo Therapeutics Stock Performance

Lexeo Therapeutics stock traded down $0.09 during midday trading on Thursday, reaching $4.80. The stock had a trading volume of 104,790 shares, compared to its average volume of 931,649. The firm’s fifty day simple moving average is $5.32 and its 200-day simple moving average is $6.80. Lexeo Therapeutics has a 1-year low of $3.60 and a 1-year high of $10.99. The stock has a market capitalization of $377.05 million, a P/E ratio of -3.31 and a beta of 1.38.

Lexeo Therapeutics (NASDAQ:LXEO) last released its earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. On average, sell-side analysts anticipate that Lexeo Therapeutics will post -1.23 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 55,000 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $5.69, for a total value of $312,950.00. Following the completion of the transaction, the chief executive officer directly owned 340,106 shares in the company, valued at $1,935,203.14. This trade represents a 13.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 59,644 shares of company stock valued at $336,462 in the last ninety days. 2.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Lexeo Therapeutics

Large investors have recently made changes to their positions in the stock. Allworth Financial LP grew its stake in shares of Lexeo Therapeutics by 1,002.9% in the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock valued at $34,000 after buying an additional 3,079 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Lexeo Therapeutics by 69.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after acquiring an additional 1,459 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Lexeo Therapeutics in the fourth quarter valued at $37,000. California State Teachers Retirement System lifted its stake in Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after acquiring an additional 2,148 shares during the last quarter. Finally, Cerity Partners LLC bought a new position in shares of Lexeo Therapeutics in the 2nd quarter valued at about $50,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.